Show simple item record

dc.contributor.authorKumar, Naresh
dc.contributor.authorGarg, Ankit
dc.contributor.authorBhatt, Deepak, L.
dc.contributor.authorSabongui, Sandra
dc.contributor.authorChaudhry, Sundeep
dc.contributor.authorArena, Ross
dc.contributor.authorVerma, Subodh
dc.date.accessioned2019-01-14T18:48:27Z
dc.date.available2019-01-14T18:48:27Z
dc.date.issued2018-11
dc.identifier.issn0008-4212
dc.identifier.other10.1139/cjpp-2018-0359
dc.identifier.urihttp://hdl.handle.net/10027/23222
dc.descriptionCopyright @ NRC Research Pressen_US
dc.description.abstractSodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to prevent heart failure and reduce cardiovascular death in patients with type 2 diabetes (T2DM) and cardiovascular disease (CVD). Whether or not SGLT2 inhibitors improve indices of cardiorespiratory fitness (CRF), an independent predictor of mortality in patients with CVD, remains unknown. We evaluated the effects of empagliflozin on indices of CRF in patients with T2DM. Twenty patients with T2DM received either empagliflozin 10 mg or usual care. Baseline and 3- to 6-month post-treatment measurements of CRF were evaluated using cardiopulmonary exercise testing on a cycle ergometer. Treatment with empagliflozin led to an increased peak oxygen consumption (VO2), reduction in VE/VCO2 slope, and improvement in heart rate recovery. Our results suggest that SGLT2 inhibitors may improve markers of CRF in patients with T2DM. This may help provide important clues into the mechanism of benefit of SGLT2 inhibitors in clinical trials and provide a translational framework for the ongoing large studies of SGLT2 inhibitors in the treatment of heart failure.en_US
dc.language.isoen_USen_US
dc.publisherNRC Research Pressen_US
dc.subjectSGLT2 inhibitoren_US
dc.subjectcardiorespiratory fitnessen_US
dc.subjectdiabetesen_US
dc.subjectfonction cardiaqueen_US
dc.subjectforme cardio-respiratoireen_US
dc.subjectheart functionen_US
dc.subjectheart failureen_US
dc.titleEmpagliflozin improves cardiorespiratory fitness in type 2 diabetes: Translational implicationsen_US
dc.typeArticleen_US
dc.identifier.citationKumar, N., Garg, A., Bhatt, D. L., Sabongui, S., Gupta, N., Chaudhry, S., . . . Verma, S. (2018). Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: Translational implications. Canadian Journal of Physiology and Pharmacology, 96(11), 1184-1187. doi:10.1139/cjpp-2018-0359en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record